<b>Objective:</b> We investigate long term clinical efficacy of
fenofibrate use on mortality and cardiovascular outcomes in patients with type 2
diabetes.
<p><b>Research design
and Methods: </b>We performed population based cohort study using data of
Korean National Health Insurance from 2003 to 2014. Among 63727 participants
with diabetes aged 40-79, 5057 users of fenofibrate only were compared with
5057 non-users of fenofibrate and/or omega-3
fatty acid with 1:1 propensity matching. Primary endpoint was composite
of myocardial infarction, stroke, percutaneous coronary revascularization and cardiac
death for median 3 years. </p>
<p><b>Results:</b> Primary endpoint was significantly lower in fenofibrate
users as compared to neither
users, 13.4 vs. 15.5 per 1000 person years (hazard ratio [HR] 0.76, confidence
interval [CI], 0.62-0.94, P=0.010). Cardiac death (1.8 vs. 3.1 per 1000 person
years [HR 0.59, CI, 0.352- 0.987, p=0.0446]), all cause death (7.6 vs. 15.3 per
1000 person years [HR 0.437, CI, 0.340 -0.562, p<0.0001]), and stroke (6.5
vs. 8.6 per 1000 person years [HR 0.621, CI, 0.463-0.833, P=0.0015]) were
significantly lower in fenofibrate group. As the duration of fenofibrate use
stratified by quartiles (Q1-4), the risk decreased in Q4 with HR of 0.347 (95%
CI 0.226-0.532, P<0.0001). In subgroup analysis, the favoring effect of
fenofibrate is sustained consistently across all subset of patients including those
classified by LDL-C, HDL-C and TG levels.</p>
<p><b>Conclusions:</b> Use of fenofibrate was associated with lower rate of total
and cardiac mortality and cardiovascular events in type 2 diabetes patients for
3 year follow-up in real world large populations.</p>